Citi analyst Yigal Nochomovitz removed Puma Biotechnology from his firm's Focus List and lowered his price target for the shares to $67 from $151. The analyst says negative factors, including an "underwhelming" Q3 report, increasing discontinuations, Puma restating patients on active therapy lower, and management commentary on new additions not supporting acceleration, force him to "significantly" reduce his forecasts. Nerlynx's launch curve still points to ~3,300 U.S. adjuvant patients, implying peak U.S. adjuvant sales of $500M, says the analyst. This is below his prior ~$1B estimate. However, Nochomovitz believes Puma's revenue picture still supports a Buy rating. He keeps a Buy rating on the shares.